CONTEXT: Another commercial announcement from Verantos. Regular readers will remember them inking a deal back in March with Amgen to launch an advanced RWE program focused on “high-validity” observational studies. This time they have teamed up with Datavant. Busy times in Paolo Alto.
IMPACT: Low
READ TIME: 1 min
Quality Level Mean [1 – 10]: 5
1. “”Both Datavant and Verantos share a mission to bring the power of real-world evidence to ensure that therapies can most efficiently reach the patients who need them the most.”
2. “PALO ALTO, Calif., May 3, 2021 /PRNewswire/ — Datavant, the leader in helping healthcare organizations safely connect their data, and Verantos, the market leader in regulatory-grade electronic health record (EHR)-based studies, today announced a strategic partnership to enable Verantos to utilize additional linked data sources to support its regulatory and reimbursement studies for its partners.”
3. “Verantos’s platform and expertise enables its life sciences partners to use advanced real-world evidence in both regulatory and reimbursement studies.”
4. “The Verantos RWE platform integrates heterogenous real world data sources and generates evidence with the accuracy necessary for regulatory and reimbursement use.”
5. “The Verantos RWE platform leverages data science and artificial intelligence along with advanced data sources such as electronic health records to generate RWE capable of supporting clinical assertions.”